Prevention of Microbial Contamination - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Prevention of Microbial Contamination
A holistic approach to establishing robust control measures.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 62-65

A recent bestseller tackled the question of why an entire nation can be compelled to help one or a few people in life-threatening situations (e.g., Chilean miners), but will do little to help millions who are at equal or greater risk (e.g., tsunami victims) (1). This concept may be irrational, but it is an accurate portrayal of the difficulty in working toward abstract goals based on concepts or proportions that are near impossible to grasp. Saving one nearby person is far easier to conceptualize than saving millions who are suffering in a distant land. In situations such as these, the tendency is to turn away because we cannot visualize how to effect change in something that we do not understand. This phenomenon also plays a role in environmental control of drug-manufacturing spaces. We are asking personnel to exercise a great deal of caution and follow rigid protocols designed to prevent contamination of the drug by invisible entities that number in the millions. To put it simply, those who work in crucial manufacturing areas have an innate tendency to underestimate the impact they have on controlling a large complex system, nevermind what subsequent effect that may have on public health, which really can be the outcome of poor manufacturing control as evidenced by recent influenza vaccine shortages and product recalls (2,3).

Effective management of drug-manufacturing areas requires a holistic approach based on identifying and monitoring those components that play the most critical roles: facility (design and conditions), personnel (training and management), and microbial control programs (products and application). A holistic, multidisciplinary approach relies heavily on metrics to address and understand the behaviors of complex systems.

Facility design


Figure 1: Water damaged wall covered with mold. (FIGURE 1: PHOTO BY JIM POLARINE)
The best defense is a good offense, especially when there are millions of dollars and the public health at stake—not hyperbole when talking about vaccines and other biotechnology derived drugs. In these cases, where terminal sterilization is typically not an option, a strong offensive position begins with a robust facility design that insulates the drug and packaging components from sources of contamination. This design must include adequate barriers (e.g., interlocking doors, clear zone demarcation), enough HVAC capacity to handle seasonal fluctuations in temperature and humidity, water control (e.g., placement of drains and water-for-injection drops), cleanable design features (e.g., smooth coving, limited obstructions), and the selection of chemical and moisture resistant materials of construction (e.g., 316L stainless steel, epoxy or polymeric flooring) to name but a few considerations. When budget, time, and expertise is unlimited, design and construction of a drugmanufacturing facility optimized to prevent product contamination can be easily achieved. However, in a less-than-optimized environment, the design and facility condition are often contributing factors to microbial excursions, and in some cases, product contamination.


Figure 2: Biofilm formation in pipes. (FIGURE 2: ADAPTED WITH PERMISSION FROM MONTANA STATE U. CENTER FOR BIOFILM ENGINEERING)
Even stainless steel may suffer the effects of chemical exposure, or overexposure, resulting in rust. Rust and pitting present challenges to effective microbial control in two ways: by providing shelter to microorganisms and residue, and by inhibiting cleaning and decontamination agents from reaching microbes to achieve adequate contact time. Stainless steel is not the only surface that can be damaged. Epoxy and polymeric floors can suffer significant damage from high foot traffic or the force of moving heavy equipment—and are not immune to the effects of significant chemical exposure. Both scenarios may lead to pooling water and associated microbial control problems, such as mold and Bacillus proliferation. Significant water damage to the structure can lead to endemic problems with molds and Bacillus (see Figure 1). Drainage issues can result in biofilm formation (see Figure 2), which cause significant, recurring problems with Bacillus and other bacteria due to increased resistance to antimicrobial chemistries demonstrated by biofilms (4).

Another necessity of good design is the inclusion of sufficient barriers to isolate the drug manufacturing process. Older facilities or facilities that were not originally designed for this purpose may not have an ideal barrier design. The warehouse or component staging areas, for example, may not be ideally located to prevent egress of undesirable particulate. It may not be possible to establish one-way traffic because of structural limitations. In both cases, contamination control is more problematic and, consequently, the drugmanufacturing process is more difficult to manage.

The most common approach to microbial control problems due to facility design flaws or damage is to increase the use of chemical antimicrobial products by concentration, frequency, or both. Extremely aggressive chemical agents, such as acidified bleach, may also be used on a short-term basis. While these measures may result in immediate improvements in environmental monitoring data, in the long run, this approach may lead to even more damage and, thus, less ability to control the environment in the future. The best solution to establish a high degree of control is to repair or retrofit the facility as required, which, although costly, is perhaps less expensive than the alternative of chasing root causes of microbial excursions or product contamination and rejection.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here